Rhythm Pharmaceuticals, Inc.
Clinical trials sponsored by Rhythm Pharmaceuticals, Inc., explained in plain language.
-
New hope for rare obesity: 2-Year drug trial launches
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety and effectiveness of bivamelagon in 25 people with hypothalamic obesity, a rare condition that causes severe weight gain. Participants who completed a prior study can join this 2-year extension. The goal is to see if the drug helps control we…
Phase: PHASE2 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 11:22 UTC
-
Promising drug targets severe hunger in rare genetic disorder
Disease control OngoingThis study tests a daily injection called setmelanotide in 18 people aged 6 to 65 with Prader-Willi syndrome, a condition causing severe obesity and constant hunger. The goal is to see if the drug safely reduces body weight and controls appetite over 52 weeks. Participants must h…
Phase: PHASE2 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 11:08 UTC
-
New hope for rare obesity: setmelanotide safety trial expands
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called setmelanotide in people aged 2 and older with rare genetic obesity. Participants must have already been in a setmelanotide study and shown benefit. The goal is to monitor side effects over time.
Phase: PHASE3 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 18, 2026 12:11 UTC
-
Hope for genetic obesity: new drug targets root cause
Disease control OngoingThis study tests a drug called setmelanotide in people aged 6 to 65 with obesity linked to specific gene variants (POMC, PCSK1, LEPR, SRC1, or SH2B1). Participants are randomly assigned to receive the drug or a placebo to see if it helps reduce body weight and BMI. The goal is to…
Phase: PHASE3 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 18, 2026 12:03 UTC